Abnova (Taiwan) Corporation. Share Price Taipei Exchange
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- TWD | - |
|
05-09 | Abnova Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
05-08 | Abnova Corporation Announces Establishment of Risk Management Committee | CI |
Sales 2022 | 412M 12.64M 1B | Sales 2023 | 382M 11.73M 929M | Capitalization | 2.13B 65.27M 5.17B |
---|---|---|---|---|---|
Net income 2022 | 74M 2.27M 180M | Net income 2023 | 43M 1.32M 105M | EV / Sales 2022 | 5.2 x |
Net cash position 2022 | 356M 10.92M 865M | Net cash position 2023 | 415M 12.75M 1.01B | EV / Sales 2023 | 4.48 x |
P/E ratio 2022 |
33.5
x | P/E ratio 2023 |
48.8
x | Employees | - |
Yield 2022 |
1.94% | Yield 2023 |
2.05% | Free-Float | 75.68% |
Managers | Title | Age | Since |
---|---|---|---|
Pei Ju Jih
CEO | Chief Executive Officer | - | 30/06/18 |
Wilber Huang
CHM | Chairman | 58 | - |
I Ling Tung
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Yueh Hung Chen
BRD | Director/Board Member | 60 | 18/06/20 |
Wilber Huang
CHM | Chairman | 58 | - |
Jia Hsie Lin
BRD | Director/Board Member | 73 | 22/06/17 |
1st Jan change | Capi. | |
---|---|---|
+16.22% | 122B | |
+21.53% | 116B | |
+22.18% | 27.03B | |
-21.83% | 20.36B | |
-16.89% | 16.43B | |
-18.07% | 15.91B | |
-44.74% | 15.6B | |
+61.56% | 14.94B | |
+3.18% | 13.59B |